KRAS and pancreatic neoplasm: Across the different cancer models, four out of sixteen cell lines: colorectal carcinoma cell line Colo-205, pancreatic cancer cell line MiaPaca-2 and lung cancer cell lines NCI-H460 and PC9 had robust knockdown of KRAS mRNA with a low IC50 (<600 nM) in response to AZD4785 treatment.